Amsterdams Aescap Venture leidt financiering 6 miljoen in f-Star

Aescap announced that it has led a Euro 6.0 million in a Series A financing round in Vienna based antibody company f-Star with a 3 million investment. Seed Investor Atlas Venture provided the other 3 million of this funding round.

f-Star is an antibody engineering company based in Vienna, Austria. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragment. This will lead to improved existing antibody therapies in a range. It is hard nowadays to find an antibody technology that is both broadly applicable and has strong IP protection. f-Star's Modular Antibody Technology is

one of these rare case's.